DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
about
Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-AnalysisLong-term outcomes of heart transplant recipients with hepatitis C positivity: the data from the U.S. transplant registry.Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis.Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Do we really need more evidence to use hepatitis C positive donor kidney more liberally?Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.Direct acting antiviral agents-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study.Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis.Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study.Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney.Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen.Hepatitis C and renal transplantation in era of new antiviral agents
P2860
Q28077287-84753F94-2754-42CA-BAF8-C37FF6F83E7CQ31136569-420C7E02-4A02-4551-8504-754735D01DA1Q33440016-773B1E4B-7506-4A7D-A8C6-FA7037C9C527Q36220536-E0CD6E3B-C5A7-47CF-80B9-4FE84B575B57Q38611051-BE39C70B-C765-4DE6-8972-E9288268AC58Q38786027-5A5F16CF-E2F2-453F-986F-72C115A2F93CQ39092977-DF4E7567-61B0-4AB7-B2F8-8F9DFE75BEEBQ40051223-CFD1B911-CB32-4C8B-9C34-B0823A2006ECQ40089989-7CBCFB09-223D-4CF5-869D-8F5B3B4CB827Q40107697-C3416EAD-DE63-4863-BCB9-31AF09629932Q40396755-63959F76-F4D2-431F-855D-80D27B21D8ACQ41608541-1210F856-1D09-44EE-9B7B-DA5911ED900BQ45325791-28DB81D4-1F06-4DE6-AA3E-9EADDD49E406Q47108436-0BD8FB25-3D48-4716-ADF7-FB4941997B4CQ58792851-7013A8DF-A2F1-4FCE-9F02-D5AD5B21B69D
P2860
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
DAA-based antiviral treatment ...... idney transplantation setting.
@en
DAA-based antiviral treatment ...... idney transplantation setting.
@nl
type
label
DAA-based antiviral treatment ...... idney transplantation setting.
@en
DAA-based antiviral treatment ...... idney transplantation setting.
@nl
prefLabel
DAA-based antiviral treatment ...... idney transplantation setting.
@en
DAA-based antiviral treatment ...... idney transplantation setting.
@nl
P2093
P2860
P356
P1476
DAA-based antiviral treatment ...... idney transplantation setting.
@en
P2093
Albert Friedrich Stättermayer
Alice Schmidt
Andreas Maieron
Bruno Watschinger
Clarissa Freissmuth
Harald Hofer
Heinz Zoller
Karin Kozbial
Michael Strasser
Michael Trauner
P2860
P304
P356
10.1111/TRI.12799
P577
2016-05-20T00:00:00Z